Peter Kissinger Net Worth

The estimated Net Worth of Peter Kissinger is at least 14.5 千$ dollars as of 20 September 2016. Peter Kissinger owns over 28,605 units of Chembio Diagnostics stock worth over 14,504$ and over the last 13 years Peter sold CEMI stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Peter Kissinger CEMI stock SEC Form 4 insiders trading

Peter has made over 3 trades of the Chembio Diagnostics stock since 2014, according to the Form 4 filled with the SEC. Most recently Peter exercised 28,605 units of CEMI stock worth 80,094$ on 20 September 2016.

The largest trade Peter's ever made was exercising 28,605 units of Chembio Diagnostics stock on 20 September 2016 worth over 80,094$. On average, Peter trades about 5,255 units every 112 days since 2011. As of 20 September 2016 Peter still owns at least 31,531 units of Chembio Diagnostics stock.

You can see the complete history of Peter Kissinger stock trades at the bottom of the page.

What's Peter Kissinger's mailing address?

Peter's mailing address filed with the SEC is 3661 HORSEBLOCK ROAD, , MEDFORD, NY, 11763.

Insiders trading at Chembio Diagnostics

Over the last 20 years, insiders at Chembio Diagnostics have traded over 909,824$ worth of Chembio Diagnostics stock and bought 3,754,893 units worth 1,696,058$ . The most active insiders traders include Credit Advisors, Llcpercept...、Lawrence A. Siebert、Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of 36,203$. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth 109,552$.

What does Chembio Diagnostics do?

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Complete history of Peter Kissinger stock trades at Chembio Diagnostics

Chembio Diagnostics executives and stock owners

Chembio Diagnostics executives and other stock owners filed with the SEC include:

• Javan Esfandiari,
  Exec. VP and Chief Science & Technology Officer
• Richard L. Eberly,
  Pres, CEO & Director
• Javan Esfandiari,
  Executive Vice President, Chief Scientific And Technology Officer
• Neil Goldman,
  Chief Financial Officer, Executive Vice President
• Katherine Davis,
  Independent Director
• John Potthoff,
  Independent Director
• Gail Page,
  Executive Chairman of the Board
• Mary Polan,
  Independent Director
• Lynn Lewis,
  Investor Relations Contact Officer
• Chuck Caso,
  Vice President of Sales and Marketing for North America
• Richard Eberly,
  President, Chief Executive Officer, Director
• Stella Rivera,
  VP of HR
• Atif Rizvi,
  VP of Fin.
• Dr. Konstantin Lyashchenko,
  Research Director of Chembio Diagnostic Systems Inc
• Charles Caso,
  VP of Sales & Marketing
• Paul J. Angelico,
  VP of Global Operations
• Peter Kissinger,
  Director
• Richard J Larkin,
  Chief Financial Officer
• Barbara A De Buono,
  Director
• John J Iii Sperzel,
  CEO
• Robert L Aromando,
  Sr VP, Commercial Operations
• Alan Carus,
  Director
• Lawrence A. Siebert,
  President
• Leslie Teso Lichtman,
  
• Norman H Pessin Brian L. Pe...,
  
• Gary Meller,
  Director
• Sharon W Klugewicz,
  Chief Operating Officer
• David Gyorke,
  See Remarks
• Robert Passas,
  See Remarks
• Avi Pelossof,
  Vice President
• Gerald A Eppner,
  Director
• James D Merselis,
  Director
• Capital Master Llc Crestvie...,
  
• David Acheson,
  
• Credit Advisors, Llcpercept...,
  
• David William Bespalko,
  
• Lawrence J. Steenvoorden,
  See remarks
• Charles Caso,
  See Remarks
• Paul Angelico,
  See remarks